Phenomenex Invests RMB 100 Million to Expand Production Capacity, Further Strengthening TEDA’s Biopharmaceutical Foreign Investment Ecosystem

On November 9, the Capacity Upgrade Inauguration Ceremony for the Phenomenex Tianjin R&D and Manufacturing Base, a subsidiary of Danaher Corporation, was held in the Tianjin Economic-Technological Development Area (TEDA). The company plans to invest approximately RMB 100 million to upgrade its production lines, strengthening its R&D and manufacturing capabilities for liquid chromatography columns and chromatographic packing materials. With the continuous expansion of high-performance liquid chromatography (HPLC) product capacity, the facility aims to achieve a production volume by 2029 that is nearly three times its 2026 level. This expansion will provide robust localized supply support for the nucleic acid therapeutics and biopharmaceutical industries.

In 2005, Phenomenex established an R&D center in TEDA, which was its second center globally and the first in Asia. The local R&D team has since achieved continuous breakthroughs, successfully launching multiple products globally. This milestone signifies a strategic shift for foreign-invested enterprises in Tianjin from "local production" to "indigenous innovation benefiting the global market."

Phenomenex's reinvestment serves as a vivid example of the sustained clustering effect of foreign investment in TEDA. Currently, TEDA has developed a nationally competitive, state-level biopharmaceutical industrial cluster, gathering over 400 industrial leaders domestically and internationally including Novo Nordisk, CanSinoBIO and Asymchem. It stands as the core growth engine of Tianjin’s biopharmaceutical industry.

Leveraging its mature industrial foundation, optimized business environment, and lifecycle government services, TEDA will continue to strengthen cutting-edge sectors such as nucleic acid therapeutics and biomanufacturing. Through its "1+3" service platform and industrial clusters, TEDA aims to consolidate innovation resources across the Beijing-Tianjin-Hebei region and attract continued foreign investment in capacity expansion and R&D. It will build an integrated biopharmaceutical innovation hub encompassing R&D, pilot scale-up, clinical trials, and commercial manufacturing, ultimately fostering a globally competitive industrial cluster.